A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2007
At a glance
- Drugs Radafaxine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 22 Jun 2007 Status changed from in progress to completed.
- 01 Oct 2005 New trial record.